Levin Capital Strategies’s Aurinia Pharmaceuticals AUPH Stock Holding History

Levin Capital Strategies’s Portfolio AUPH Stock Details AUPH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q1	–	Sell	-10,000	Closed	-$68K	–	194
2018 Q4	$68K	Hold	10,000	–	–	﹤0.01%	244
2018 Q3	$66K	Hold	10,000	–	–	﹤0.01%	263
2018 Q2	$56K	Hold	10,000	–	–	﹤0.01%	278
2018 Q1	$52K	Hold	10,000	–	–	﹤0.01%	297
2017 Q4	$45K	Hold	10,000	–	–	﹤0.01%	298
2017 Q3	$63K	Buy	+10,000	New	+$63K	﹤0.01%	333

Other funds holding AUPH

NMC

NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

CCM

Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return

Polar Capital London, United Kingdom $13.5B AUM 55.9% 1-Year Est. Return

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Levin Capital Strategies's AUPH Position: Q1 2019 in Review

Levin Capital Strategies sold out of Aurinia Pharmaceuticals (AUPH) in Q1 2019, closing a stake of 10,000 shares — an estimated $68K sold.

Levin Capital Strategies first reported a position in AUPH in Q3 2017 and held it in 6 quarters. The position peaked at $68K in Q4 2018. 78 funds tracked by Wall St. Rank hold AUPH as of Q1 2019.

Levin Capital Strategies reported no remaining Aurinia Pharmaceuticals position as of Q1 2019 after selling out during the quarter.
Levin Capital Strategies sold 10,000 Aurinia Pharmaceuticals shares in Q1 2019, an estimated $68K.
Levin Capital Strategies first reported a position in Aurinia Pharmaceuticals in Q3 2017 and held it in 6 quarters.
Levin Capital Strategies's Aurinia Pharmaceuticals position peaked at $68K in Q4 2018.
78 funds tracked by Wall St. Rank held Aurinia Pharmaceuticals as of Q1 2019.

Based on Levin Capital Strategies's 13F filing for Q1 2019, filed 13 May 2019.